dgn-np:NP108463.RAvEIeaKSDfqTj_bh6IfH92u-OyFiLNo-c7oiiwzCKKkc130_provenance {
  dgn-np:NP108463.RAvEIeaKSDfqTj_bh6IfH92u-OyFiLNo-c7oiiwzCKKkc130_assertion dcterms:description "[This analysis evaluated the influence of potential prothrombotic risk factors (antithrombin, protein C, protein S, factor V Leiden mutation, prothrombin gene G20210A mutation, cardiolipin antibodies, number of risk factors) on the risk of recurrent VTE or bleeding during treatment with oral ximelagatran (24 mg twice daily) or placebo for 18 months THRombin Inhibitor in Venous thromboEmbolism (THRIVE) III trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ;
    wi:evidence dgn-void:source_evidence_literature ;
    sio:SIO_000772 miriam-pubmed:16512831 ;
    prov:wasDerivedFrom dgn-void:gad-20150221 ;
    prov:wasGeneratedBy eco:ECO_0000203 .
  dgn-void:gad-20150221 pav:importedOn "2015-02-21"^^xsd:date .
  dgn-void:source_evidence_literature a eco:ECO_0000212 ;
    rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en ;
    rdfs:label "DisGeNET evidence - LITERATURE"@en .
}